02 / Genome Research · 2018
A hidden RNA switch connected to patient outcomes.
Discovery at scale: approximately 6,000 RNA-seq samples.
AN ASSUMPTION PUT TO THE TEST
The assumption I challenged
An almost unchanged AFMID total suggested little to investigate. Tumour heterogeneity made reproducible splicing patterns seem unlikely, while existing approaches struggled to capture complex changes involving several exons.
What we showed
AFMID’s overall expression barely changed, but the balance of its RNA versions did. The human-specific switch was already present in early liver cancer and associated with poorer outcomes.
My contribution
I developed an analysis for complex splicing events and applied it across approximately 6,000 RNA-seq samples, connecting the switch with clinical and molecular evidence.
The evidence we established
Its recurrence association had similar statistical significance to MKI67, the gene encoding the familiar proliferation marker Ki-67.
Why it matters
The integrative analysis connected an RNA splicing switch with the production of NAD+, a molecule important for metabolism and DNA repair, cancer-driving mutations, and liver-cancer recurrence. It uncovered a mechanistic link that gene totals alone had missed—and a biological pathway to investigate for biomarkers and treatment strategies.
An unchanged total can hide a biological switch.
Explore the evidence & discovery process
- 01Testing a complex splicing event
- The PSI analysis represented changes involving several skipped exons. The approximately 6,000 RNA-seq samples included liver tissues, different cell types, and cancer cell lines across datasets.
- 02Examining patient outcomes
- Low versus high full-length AFMID splicing yielded reported hazard ratios of 1.7087 for death (P = 0.0035) and 1.8822 for recurrence (P = 3.60 × 10⁻⁵). Similar recurrence P-values for AFMID and MKI67 do not establish equal predictive accuracy; the analysis limitations are described below.
- 03Distinguishing tumour biology
- Lower full-length AFMID was associated with TP53 mutations. CTNNB1—another common liver-cancer driver—showed no significant enrichment despite a similar mutation frequency. This raised the question of whether the switch helps distinguish biologically different forms of liver cancer.
- 04Choosing the relevant experimental model
- The switch was human-specific. An unmodified mouse does not directly reproduce that splicing event; experiments must use a system that captures the human mechanism.
- 05Testing the biological effect
- The team increased full-length AFMID in HepG2 liver-cancer cells. NAD⁺ levels rose and cell growth slowed, providing experimental support for a connection between the RNA switch and cell metabolism (Figure 4).
- 06The next question
- Does the RNA-version balance improve prediction in independent patient cohorts, and do the effects seen in cell culture extend to other relevant models?
Technical context & publication
AFMID produces alternative RNA isoforms. The study analyzed approximately 6,000 RNA-sequencing samples across human and other biological datasets. In the reported qPCR comparison of 20 adjacent non-tumour livers and 19 HCCs, overall AFMID expression did not change significantly, while the full-length isoform decreased. A human-specific switch does not make mouse models universally uninformative; it limits their direct use for this mechanism without appropriate engineering. Figure 2C,D reports median-split PSI comparisons in TCGA LIHC: 130 patients for survival and 174 for recurrence, after excluding right-censored records with follow-up information only. That exclusion limits interpretation and generalization of the reported hazard ratios; they are not individual absolute risks or proof of independent predictive value. The recurrence log-rank P-value was similar to that for MKI67 (3.80 × 10⁻⁵), but similar P-values do not establish equivalent prediction accuracy. Across 369 HCCs, low-MKI67 samples had higher AFMID full-length PSI (P = 3.71 × 10⁻⁷). These associations motivate validation with appropriate censoring and adjustment for other prognostic factors. In the reported nonsilent-mutation comparison across 369 HCCs, 37 of 54 TP53-mutant samples fell in the low-AFMID full-length group (hypergeometric P = 0.0016). TTN and CTNNB1 were mutated in similar numbers of samples but showed no significant enrichment. CTNNB1 is a recognized HCC driver, not a passenger-gene comparator. These are reported enrichment tests, not proof that the associations differ statistically from one another or that the splicing switch causes TP53 mutations; absence of significance is not proof of no association. ARID1A enrichment was reported in the separate extreme-quartile analysis.
Read the Genome Research paper ↗